| Name | Title | Contact Details |
|---|
AZPerio is home to the state’s leading board-certified periodontists, expertly guided by a patient-first philosophy and collaborative approach. With eight locations throughout Arizona, we are committed to client service, clinical excellence and providi...
UCS Healthcare is a healthcare organization offering a variety of services from medical to treatment.
arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.
Reset Therapeutics is a biopharmaceutical company formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body`s network of internal molecular clocks. The circadian system synchronizes behavioral and physiological processes, including sleep, metabolism, feeding, blood pressure and hormone secretion with the environmental cycles of light, activity and nutrient status. Disruption of normal circadian rhythms is associated with many diseases, including central nervous system, cardiovascular and metabolic disorders, immune system dysfunction and cancer. Novel therapies that reset the body’s biological clocks have the potential to benefit very large and diverse patient populations